<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04364776</url>
  </required_header>
  <id_info>
    <org_study_id>20200008978</org_study_id>
    <nct_id>NCT04364776</nct_id>
  </id_info>
  <brief_title>Radiomic Signature as Predictive Marker of Response to Chemoradiation and Durvalumab in Stage III NSCLC.</brief_title>
  <official_title>Blue Sky Radiomics: an Observational Study on Computed Tomography as an Image-based Predictive Marker of Response to Chemoradiation Followed by Durvalumab in Stage III Unresectable Non-small Cell Lung Cancer (NSCLC).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Policlinico S. Matteo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS Policlinico S. Matteo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The introduction of maintenance immunotherapy with the anti PD-L1 inhibitor durvalumab opened&#xD;
      a new therapeutic window for stage III NSCLC patients who achieve at least stable disease&#xD;
      after chemo-radiation, as shown by the randomized phase 3 PACIFIC study. However, still half&#xD;
      of the patients do progress at 12 months (up to 70% at 18 months). In this study, the&#xD;
      investigators aim to test a non-invasive image-based approach, namely a &quot;radiomics&quot; platform,&#xD;
      as a tool to define a higher or lower likelihood of response to chemo-radiation and&#xD;
      durvalumab. For this purpose, we will retrospectively and prospectively collect and analyze a&#xD;
      cohort of at least 70 stage III NSCLC patients treated with CT-RT followed by maintenance&#xD;
      durvalumab.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Specific aim (one):&#xD;
&#xD;
      To collect and analyze CT scans at diagnosis and after chemoradiation, and assign them to a&#xD;
      specific radiomic signature (blind assessment).&#xD;
&#xD;
      Specific aim (two):&#xD;
&#xD;
      - To correlate the radiomics signatures to clinical outcome: the main measure will be&#xD;
      progression-free survival at 6 months, the second will be overall survival at 24 months.&#xD;
&#xD;
      This is an observational longitudinal retrospective/prospective study.&#xD;
&#xD;
      Criteria for study entry:&#xD;
&#xD;
        -  Histologically or cytologically confirmed diagnosis of non-small cell lung cancer&#xD;
           (NSCLC)&#xD;
&#xD;
        -  Age 18-80&#xD;
&#xD;
        -  Stage IIIA-C disease judged to be unresectable by a multidisciplinary team including&#xD;
           pulmonologists, thoracic surgeons, medical and radiation oncologists.&#xD;
&#xD;
        -  Signed informed consent&#xD;
&#xD;
      Exclusion criteria:&#xD;
&#xD;
        -  Inability to sign the informed consent&#xD;
&#xD;
        -  Absence of analyzed CT images&#xD;
&#xD;
      Treatment:&#xD;
&#xD;
      As per indication, patients should have received a thoracic radiation dose of at least 54 Gy&#xD;
      to the primary tumor and lymph nodes; all techniques are allowed. Conventional fractionation&#xD;
      or mild hypofractionation is also allowed. All different platinum-based chemotherapy regimens&#xD;
      are admitted for the present study in combination with radiotherapy, given either&#xD;
      concomitantly or sequentially, according to International Guidelines for combination therapy&#xD;
      in locally advanced NSCLC.&#xD;
&#xD;
      Radiomic data extraction: after a pilot harmonization study phase, all CT scans will be&#xD;
      analyzed using two different pre-defined signatures. The first one was developed by the&#xD;
      Institut Gustave Roussy, Paris, and the second one by Radiomics (Liegi, Belgium). These two&#xD;
      signatures have been either linked to response to anti PD1 or to chemoradiation alone.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2020</start_date>
  <completion_date type="Anticipated">April 15, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>24 months from the end of radiotherapy</time_frame>
    <description>Proportion of patients without disease progression (local, distant, or both) at 6,12,18 and 24 months, and median Progression-Free survival.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>24 months from the end of radiotherapy</time_frame>
    <description>Proportion of patients alive at 6, 12, 18 and 24 months, and median overall survival</description>
  </secondary_outcome>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Lung Cancer Stage III</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>In this observational study, durvalumab will be administered according to current indications (PACIFIC phase III trial).</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Stage III unresectable non-small cell lung cancer patients undergoing chemoradiation&#xD;
        followed by durvalumab.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed diagnosis of non-small cell lung cancer&#xD;
             (NSCLC)&#xD;
&#xD;
          -  Age 18-80&#xD;
&#xD;
          -  Stage IIIA-IIIB-IIIC disease judged to be unresectable by a multidisciplinary team&#xD;
             including pulmonologists, thoracic surgeons, medical and radiation oncologists.&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to sign the informed consent&#xD;
&#xD;
          -  Absence of analyzed CT images&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Andrea Riccardo Filippi, prof.</last_name>
    <phone>+390382503132</phone>
    <email>a.filippi@smatteo.pv.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alessandra Ferrari, dr.</last_name>
    <email>alessandra.ferrari@smatteo.pv.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandra Ferrari, dr.</last_name>
      <email>alessandra.ferrari@smatteo.pv.it</email>
    </contact>
    <investigator>
      <last_name>Andrea Riccardo Filippi, prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 24, 2020</study_first_submitted>
  <study_first_submitted_qc>April 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2020</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Policlinico S. Matteo</investigator_affiliation>
    <investigator_full_name>Andrea Riccardo Filippi</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>durvalumab</keyword>
  <keyword>radiomics</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Durvalumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

